Marco Pravetoni, PhD
The Pravetoni group focuses on development and translation of medical interventions against substance use disorders (SUD) and other chemical and biological threats. Current efforts are: 1) vaccines, monoclonal antibodies (mAb), and small molecules to treat or prevent SUD, opioid use disorders (OUD) and overdose, 2) mechanisms and biomarkers underlying or predicting efficacy of immunotherapeutics and medications in pre-clinical models of SUD and OUD patients, 3) novel strategies to enhance vaccine or medication efficacy, including immunomodulators, small molecules, adjuvants, nanoparticles, polymers and other delivery platforms, 4) Vaccines, mAb, and clinical biomarkers against infectious diseases (e.g., Pseudomonas aeruginosa and novel coronavirus SARS-CoV-2), 5) biosensors for field detection or diagnosis.
Education
PhD in Pharmacology, University of Minnesota, 2008
Department Affiliations
Scholarly Expertise
- Vaccines, monoclonal antibodies, immunology, pharmacology, chemical threats, immunoprofiling
Recent Publications
(2024 Oct 11)
J Immunol
Dick JK, Sangala JA, Krishna VD, Khaimraj A, Hamel L, Erickson SM, Hicks D, Soigner Y, Covill LE, Johnson AK, Ehrhardt MJ, Ernste K, Brodin P, Koup RA, Khaitan A, Baehr C, Thielen BK, Henzler CM, Skipper C, Miller JS, Bryceson YT, Wu J, John CC, Panoskaltsis-Mortari A, Orioles A, Steiner ME, Cheeran MCJ, Pravetoni M, Hart GT
(2025 Feb)
Biomaterials 313(): 122758
Walter DL, Bian Y, Hu H, Hamid FA, Rostamizadeh K, Vigliaturo JR, DeHority R, Ehrich M, Runyon S, Pravetoni M, Zhang C
(2024 Sep 1)
J Immunol 213(5): 663-668
Khaimraj A, Baehr CA, Hicks D, Raleigh MD, Pravetoni M
(2024 Jun 21)
bioRxiv
Dick JK, Hicks D, Krishna VD, Sangala JA, Zandstra BT, Baehr C, Verbeek JS, Cragg MS, Cheeran MC, Pravetoni M, Hart GT
(2024 Aug)
J Biol Chem 300(8): 107502
Gallant JP, Hicks D, Shi K, Moeller NH, Hoppe B, Lake EW, Baehr C, Pravetoni M, Aihara H, LeBeau AM
Show complete publication list »
